Trial Profile
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 01 Oct 2005 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met, according to results published in Diabetes, Obesity and Metabolism.
- 01 Oct 2005 New trial record.